The body knows how to heal. Regentron is building the systems to help direct it
Two decades+ of scientific and clinical work • 20-asset IP estate
Functioning technical systems • Historical technical proof
Regentron does not begin from a blank page
A coherent patent estate, functioning equipment, and documented historical clinical experience — assembled over more than twenty years, not around a single market opportunity.
IP assets
17 granted or in force, 2 pending, 1 in preparation. All registered in the Russian Federation; international filings are a funded workstream.
Scientific & clinical work
Research across cell biology, tissue engineering, bioprinting, and reconstruction.
Equipment & prototypes
Functioning bioreactors and delivery systems that have been built and operated.
Technical proof
Fingertip work as an early proof model for the microenvironment and delivery approach — not the commercial indication.
Four connected capabilities, usable whole or in parts
Regentron works on the layer beneath the therapy: producing viable tissue at useful thickness, holding a controlled environment at the injury site, and placing biologics precisely. Each layer can be evaluated as a modular component inside a partner program.
Existing substance, and a defined program to confirm it
Critical claims have not yet been independently reproduced under predefined international protocols. That is precisely what this financing funds — stages two and three below.
Existing foundation
Patents, prototypes, internal technical work, and historical human observations.
Independent confirmation
Evidence audit, technical and scientific replication, external review, reproducibility.
Partner-ready package
Manufacturing foundation, regulatory strategy, combination data, study readiness.
Partner-funded development
Prospective clinical execution, scale-up, and regulatory submissions.
Built to complement existing life-sciences programs
Regentron addresses development problems a counterparty would otherwise solve internally — cell retention, persistence, tissue integration, reproducible production, and localized delivery. No one need acquire the whole platform: a single indication, patent family, capability, or territory can support a standalone transaction.
Cell-therapy & pharma
Retention, persistence, engraftment, and tissue integration — addressed by the microenvironment, production, and delivery layers.
Orthopaedic & regenerative
Bone and cartilage repair limitations — addressed by the spheroid, construct, microenvironment, and delivery IP.
Wound & reconstructive medtech
Clinical workflow and tissue restoration — addressed by the lead device and the historical human signal.
Advanced manufacturing
Reproducible tissue production — addressed by the aerosol bioreactor and process know-how.
The scientists who built the platform, with founder-led execution
The scientific team is aligned as long-term equity partners, providing continuity from invention through validation and partnership.
Alexey Kovalev, MD, PhD
Principal scientific architect of the in-vivo bioreactor systems, cell-aggregate engineering, and delivery capabilities. 57 patents · 150+ publications.
Vladimir Mironov, MD, PhD
Bioengineer, physician-scientist, and a pioneer of bioprinting. H-index 58 · 22,000+ citations · 200+ publications (Google Scholar, 2026).
Konstantin Vagin
Two decades across healthcare commercialization, pharmaceutical market entry, and international venture development. Leads strategy and financing.
Capital for international validation and strategic readiness
Regentron is raising capital to advance its existing scientific, technical and intellectual-property foundation through independent international validation and into a partner-ready development program.
Detailed investor and partnering materials are available to qualified counterparties on request.